Literature DB >> 16618776

Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.

Barbara Valzasina1, Silvia Piconese, Cristiana Guiducci, Mario P Colombo.   

Abstract

The CD25- and CD25+ CD4 T-lymphocyte compartments are tightly regulated. We show here that tumors break such balance, increasing the number of CD4+CD25+ T cells in draining lymph node and spleen but not contralateral node of tumor-bearing mice. Tumor injection in thymectomized and CD25-depleted mice shows that CD4+CD25+ T-cell expansion occurs even in the absence of the thymus and independently from proliferation of preexisting CD25+ T cells. These newly generated cells are bona fide regulatory T cells (T reg) in terms of Foxp3 expression and suppression of CD3-stimulated or allogeneic effector cell proliferation. Transfer of congenic Thy1.1 CD4+CD25- T cells, from mice treated or not with vinblastine, into tumor-bearing or tumor-free mice and analysis of recovered donor lymphocytes indicate that conversion is the main mechanism for acquiring the expression of CD25 and Foxp3 through a process that does not require proliferation. Although conversion of CD4+CD25- T cells for generation of T regs has been described as a natural process that maintains peripheral T-reg population, this process is used by the tumor for immune escape. The prompt recovery of T regs from monoclonal antibody-mediated CD25 depletion in tumor-bearing mice suggests attempts able to inactivate rather than deplete them when treating existing tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618776     DOI: 10.1158/0008-5472.CAN-05-4217

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

1.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors:  Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

3.  Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Authors:  Natalia Martin-Orozco; Yufeng Li; Yijun Wang; Shijuan Liu; Patrick Hwu; Yong-Jun Liu; Chen Dong; Laszlo Radvanyi
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

4.  4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.

Authors:  Young-June Kim; Myung-Kwan Han; Hal E Broxmeyer
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 5.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

6.  Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice.

Authors:  Ana Jurin Martić; Siniša Ivanković; Mariastefania Antica; Nevenka Hiršl; Tomislav Jukić; Mislav Jurin
Journal:  Cancer Biother Radiopharm       Date:  2015-03-12       Impact factor: 3.099

Review 7.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Authors:  Nicolas Larmonier; Nona Janikashvili; Collin James LaCasse; Claire Billerey Larmonier; Jessica Cantrell; Elaine Situ; Tamara Lundeen; Bernard Bonnotte; Emmanuel Katsanis
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Authors:  Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; Steven A Rosenberg
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.